Pliant's Bexotegrast Shows Consistent Safety and Efficacy in Liver Disease Trial
TL;DR Summary
Pliant Therapeutics' drug bexotegrast shows consistent safety across dose ranges in a Phase IIa trial for primary sclerosing cholangitis (PSC), although the highest dose did not demonstrate improved activity over lower doses based on new biomarker data. Analysts remain optimistic about the drug's overall development, as it inhibits two integrins to block the activation of TGF-beta, a central mediator of fibrosis in PSC patients.
Topics:business#bexotegrast#chronic-liver-disease#fibrosis#healthcarepharmaceuticals#phase-iia-trial#pliant-therapeutics
- Pliant's chronic liver disease drug has consistent safety across dose ranges, PhII data show Endpoints News
- Pliant liver disease med passes high-dose test, but doesn't wow FierceBiotech
- Pliant Therapeutics announces data from INTEGRIS-PSC Phase 2a trial - TipRanks.com TipRanks
- Pliant Therapeutics Announces Positive Safety and Exploratory Efficacy Data from the INTEGRIS-PSC Phase 2a Trial of Bexotegrast 320 mg in Patients with Primary Sclerosing Cholangitis and Suspected Liver Fibrosis Marketscreener.com
Reading Insights
Total Reads
0
Unique Readers
1
Time Saved
0 min
vs 1 min read
Condensed
44%
115 → 64 words
Want the full story? Read the original article
Read on Endpoints News